Cover Image
市場調查報告書

糖尿病治療的全球市場分析:2015-2022年

Global Diabetic Care Market Analysis 2015-2022

出版商 BIS Research 商品編碼 347570
出版日期 內容資訊 英文 261 Pages; 152+ Figures; 12 Tables
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病治療的全球市場分析:2015-2022年 Global Diabetic Care Market Analysis 2015-2022
出版日期: 2015年12月22日 內容資訊: 英文 261 Pages; 152+ Figures; 12 Tables
簡介

本報告提供全球糖尿病治療市場相關調查分析、市場主要趨勢/促進要素/課題/機會、各糖尿病類型/生態系統企業/藥物類型/設備類型/行動應用程式開發者/終端應用/地區的市場分析、競爭狀況分析,及主要企業的簡介等彙整。

第1章 調查概要

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 全球糖尿病盛行率
  • 風險因素 & 糖尿病管理的方法
  • 糖尿病治療市場上主要趨勢
  • 成為糖尿病治療的一部分的先進技術

第4章 市場動態

  • 簡介
  • 推動市場的要素
  • 市場課題
  • 市場機會

第5章 競爭情形

  • 主要市場開發與策略
  • 波特的五力分析

第6章 產業分析

  • 法規、國際集團、認證及標準
  • 價值鏈分析

第7章 全球糖尿病治療市場:各糖尿病類型

  • 簡介
  • 第一型糖尿病
  • 第二型糖尿病
  • 妊娠性糖尿病
  • 其他糖尿病

第8章 全球糖尿病治療市場:各生態系統企業

  • 簡介
  • 糖尿病治療生態系統的分類
  • 市場統計

第9章 全球糖尿病治療市場:各藥物類型

  • 簡介
  • 市場統計
  • 全球糖尿病治療藥市場:分類、促進要素及課題
  • 全球糖尿病治療市場規模:各藥物類型
  • 藥物的開發過程
  • 藥物的種類
  • 主要的糖尿病治療藥
  • 近幾年的發展趨勢

第10章 全球糖尿病治療市場:各設備類型

  • 簡介
  • 市場統計
  • 血糖監測系統
  • 胰島素輸送設備
  • 近幾年的發展

第11章 全球糖尿病治療市場:各行動應用程式開發者

  • 簡介
  • 軟體
  • 巨量資料
  • 市場統計
  • 行動應用程式的優點
  • 糖尿病應用:種類、促進要素
  • 糖尿病治療行動應用程式市場上主要產品
  • 近幾年的發展、主要企業

第12章 全球糖尿病治療市場:各終端應用

  • 簡介
  • 市場統計
  • 病患監測
  • 診斷
  • 教育 & 意識
  • 醫療經營管理
  • 預防 & 健康
  • 治療
  • 其他
  • 近幾年主要的發展

第13章 全球糖尿病治療市場:各地區

  • 簡介
  • 市場統計
  • 南北美洲
  • 歐洲
  • 亞太地區
  • 其他 (RoW)

第14章 全球糖尿病治療市場:主要企業

  • 簡介
  • ELI LILLY AND COMPANY
  • BAYER HEALTHCARE AG
  • NOVO NORDISK
  • SANOFI PHARMA
  • MEDTRONIC INCORPORATION
  • JOHNSON & JOHNSON
  • PFIZER
  • ASTRAZENECA
  • MERCK & CO., INC
  • ROCHE DIAGNOSTICS
  • BRISTOL-MYERS SQUIBB COMPANY
  • BOEHRINGER INGELHEIM GROUP
  • ABBOTT LABORATORIES
  • 武田藥品工業
  • GLAXOSMITHKLINE PLC (GSK)
  • NOVARTIS
  • AT&T, INC.
  • AGAMATRIX, INC.

第15章 用語

圖表清單

目錄
Product Code: MD06

The gradual advancement and innovation of new Diabetic Care technologies are developing a concrete platform for further growth of Diabetic Care market. With the emergence of advanced technologies such as mobile health, precision medicine, smart sensors, wearable technologies, and 3D-printing into the field of Diabetic Care, there has been a rise in the overall demand of the newly developed Diabetic Care products. Presently, the main focus of the government initiatives is mainly towards developing non-invasive solutions, controlling the level of increase in diabetic population, and integrating advanced technologies to fulfill the unmet needs of the diabetic population.

Governmental regulations and standards are playing a major role in sustaining the growth and development of the Diabetic Care market. The main aim of these regulations is to make Diabetic Care more adaptable and focused towards different types of diabetic diseases and also provide modern mobile technologies to the diabetic population. The patients benefit indirectly through these regulations as it helps them save time and cuts-down the overall cost as the patients receive the required treatment for the disease. The Diabetic Care market growth is propelled by due to factors such as: increasing demand for non-invasive treatments, technological innovation and advancement, development of artificial pancreas, and government support and regulations.

This study includes an overview and analysis of the Diabetic Care market, by type of diabetes, ecosystem (drug manufacturers, device manufacturers and mobile application developers), end-use applications, and geographical regions, allowing the research to develop a comprehensive outlook of the market. The Diabetic Care market report presents a detailed and investigative study of the entire Diabetic Care ecosystem and provides a comprehensive insight into various forms of developments, trends and key participants. The different type of diabetes are categorized into three major categories, viz. type 1, type 2, and gestational, among others, in the report. All of the above mentioned report coverage parameters are discussed across different regions like The Americas, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the Diabetic Care market.

The answers to the following key questions can be found in the report:

  • What are the major market drivers, challenges and opportunities of the Diabetic Care market and their use cases?
  • What are the key trends and developments in the Diabetic Care market for different Diabetic Care management?
  • What are the key developmental strategies in different applications across all regions?
  • What are different types of Diabetic Care solutions and the latest Diabetic Care technologies?
  • How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launches among others?
  • Which geographical region will lead the global Diabetic Care market by the end of the forecast period?
  • Who are the key players in the Diabetic Care market?
  • What are the key government regulations for different Diabetic Care solutions?
  • What are different types of devices, drugs and mobile applications in Diabetic Care market and what are the applications in which they are being used?
  • What are the different end-use applications in which Diabetic Care products are being used?
  • What is the different used case scenarios considered under different end-use applications?
  • What are the Diabetic Care market trends and key developments in different geographical regions?

The research study tries to answer various aspects of the Diabetic Care market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion of Diabetic Care solutions. The study takes into account Porter's Five Force Model for an in-depth study of the Diabetic Care market and an assessment of the factors governing the same. The analysis builds on a well-compiled value chain giving a detailed understanding of the ecosystem market penetration in the domain of Diabetic Care.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global Diabetic Care industry is subjected to, including the estimation of the industry's growth in terms of production and revenue. The report includes the profiles of major players in the Diabetic Care market, like, Eli Lily and Company, Novo Nordisk and Sanofi Pharma among others, allowing the readers to get an insight into the various industry trends.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. REPORT SCOPE
  • 1.2. REPORT COVERAGE
  • 1.3. RESEARCH METHODOLOGY
    • 1.3.1. DATA TRIANGULATION
    • 1.3.2. TOP-DOWN APPROACH
    • 1.3.3. BOTTOM-UP APPROACH
    • 1.3.4. ASSUMPTIONS & LIMITATIONS
    • 1.3.5. KEY DATA POINT SOURCES
      • 1.3.5.1. KEY DATA POINTS FROM SECONDARY SOURCES
      • 1.3.5.2. KEY DATA POINTS FROM PRIMARY SOURCES
  • 1.4. REPORT DESCRIPTION

2. EXECUTIVE SUMMARY

  • 2.1. GLOBAL MARKET SCENARIO

3. MARKET OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. DIABETES PREVALENCE WORLDWIDE
  • 3.3. RISK FACTORS & APPROACH FOR DIABETES MANAGEMENT
  • 3.4. KEY TRENDS IN DIABETIC CARE MARKET
  • 3.5. ADVANCE TECHNOOGIES ENTERING INTO DIABETIC CARE

4. MARKET DYNAMICS

  • 4.1. INTRODUCTION
  • 4.2. MARKET DRIVERS
  • 4.3. MARKET CHALLENGES
  • 4.4. MARKET OPPORTUNITIES

5. COMPETITIVE INSIGHTS

  • 5.1. KEY MARKET DEVELOPMENT & STRATEGIES
    • 5.1.1. PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • 5.1.2. MERGERS & ACQUISITIONS
    • 5.1.3. PRODUCT DEVELOPMENTS AND LAUNCHES
    • 5.1.4. BUSINESS EXPANSION/CONTRACTS
    • 5.1.5. PATENTS, APPROVALS AND CERTIFICATIONS
    • 5.1.6. OTHERS (EVENTS & RECOGNITIONS)
  • 5.2. PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1. BARGAINING POWER OF BUYERS
    • 5.2.2. BARGAINING POWER OF SUPPLIER
    • 5.2.3. THREAT FROM SUBSTITUTE
    • 5.2.4. THREAT OF NEW ENTRANT
    • 5.2.5. INTENSITY OF COMPETITIVE RIVALRY

6. INDUSTRY ANALYSIS

  • 6.1. REGULATIONS, CONSORTIUMS, CERTIFICATION, & STANDARDS
    • 6.1.1. CONSORTIUM
    • 6.1.2. ALLIANCE/ASSOCIATIONS
    • 6.1.3. REGULATORY BODIES
      • 6.1.3.1. FOOD AND DRUG ADMINISTRATION (FDA)
      • 6.1.3.2. MEDICAL DEVICE REGULATION ACT
      • 6.1.3.3. MOBILE MEDICAL APPLICATIONS: THE FDA REGULATORY APPROACH
  • 6.2. VALUE CHAIN ANALYSIS

7. GLOBAL DIABETIC CARE MARKET BY DIABETES TYPES

  • 7.1. INTRODUCTION
  • 7.2. TYPE 1. DIABETES
  • 7.3. TYPE 2. DIABETES
  • 7.4. GESTATIONAL DIABETES
  • 7.5. OTHER DIABETES

8. GLOBAL DIABETIC CARE MARKET BY ECOSYSTEM PLAYERS

  • 8.1. INTRODUCTION
  • 8.2. DIABETIC CARE ECOSYSTEM CLASSIFICATION
  • 8.3. MARKET STATISTICS

9. GLOBAL DIABETIC CARE MARKET BY DRUG TYPES

  • 9.1. INTRODUCTION
  • 9.2. MARKET STATICS
  • 9.3. GLOBAL DIABETIC CARE DRUG MARKET: CLASSIFICATION, DRIVERS & CHALLENGES
  • 9.4. GLOBAL DIABETIC CARE MARKET VALUE, BY DRUG TYPES
  • 9.5. DRUG DEVELOPMENT PROCESS
  • 9.6. DRUG TYPES
    • 9.6.1. INSULIN
    • 9.6.2. ORAL ANTI-DIABETIC DRUGS
    • 9.6.3. NON-INSULIN INJECTABLE DRUGS
  • 9.7. SOME DIABETIC DRUGS
  • 9.8. RECENT DEVELOPMENTS

10. GLOBAL DIABETIC CARE MARKET BY DEVICE TYPES

  • 10.1. INTRODUCTION
  • 10.2. MARKET STATISTICS
  • 10.3. GLUCOSE MONITORING DEVICES
    • 10.3.1. SMBG MONITOR
    • 10.3.2. CGM DEVICE
  • 10.4. INSULIN - DELIVERY DEVICES
  • 10.5. RECENT DEVELOPMENTS

11. GLOBAL DIABETIC CARE MARKET BY MOBILE APPLICATION DEVELOPERS

  • 11.1. INTRODUCTION
  • 11.2. SOFTWARE
  • 11.3. BIG DATA
  • 11.4. MARKET STATISTICS
  • 11.5. BENEFITS OF MOBILE APPS
  • 11.6. DIABETES APPS: TYPES & DRIVERS
  • 11.7. SOME OF THE KEY PRODUCTS IN THE DIABETIC CARE MOBILE APPS MARKET
  • 11.8. RECENT DEVELOPMENTS & KEY PLAYERS

12. GLOBAL DIABETIC CARE MARKET, BY END-USE APPLICATION

  • 12.1. INTRODDUCTION
  • 12.2. MARKET STATISTICS
  • 12.3. PATIENT MONITORING
    • 12.3.1. MARKET STATISTICS
    • 12.3.2. KEY INSIGHTS, EXAMPLES & PLAYERS
  • 12.4. DIAGNOSIS
    • 12.4.1. MARKET STATISTICS
    • 12.4.2. DIAGNOSIS APPLICATION: SOME USE CASES & KEY PLAYERS
  • 12.5. EDUCATION & AWARENESS
    • 12.5.1. MARKET STATISTICS
  • 12.6. HEALTHCARE MANAGEMENT
    • 12.6.1. MARKET STATISTICS
  • 12.7. PREVENTION & WELLNESS
    • 12.7.1. MARKET STATISTICS
  • 12.8. TREATMENT
    • 12.8.1. MARKET STATISTICS
  • 12.9. OTHERS
    • 12.9.1. MARKET STATISTICS
  • 12.1. RECENT KEY DEVELOPMENTS

13. GLOBAL DIABETIC CARE MARKET, BY GEOGRAPHY

  • 13.1. INTRODDUCTION
  • 13.2. MARKET STATISTICS
  • 13.3. THE AMERICAS
    • 13.3.1. THE AMERICAS: KEY INSIGHTS
    • 13.3.2. STATISTICS OF THE KEY COUNTRIES/TERRITORIES
    • 13.3.2. MARKET STATISTICS
    • 13.3.3. THE U.S.: MAJOR MARKET SHARE HOLDER
    • 13.3.4. RECENT DEVELOPMENTS
  • 13.4. EUROPE
    • 13.4.1. EUROPE: KEY INSIGHTS
    • 13.4.2. STATISTICS OF THE KEY COUNTRIES/TERRITORIES
    • 13.4.3. MARKET STATISTICS
    • 13.4.4. RECENT DEVELOPMENTS
  • 13.5. APAC
    • 13.5.1. APAC: KEY INSIGHTS
    • 13.5.2. STATISTICS OF THE KEY COUNTRIES/TERRITORIES
    • 13.5.3. MARKET STATISTICS
  • 13.6. REST OF THE WORLD (ROW)
    • 13.6.1. AFRICA: KEY INSIGHTS
    • 13.6.2. MIDDLE EAST: KEY INSIGHTS
    • 13.6.3. STATISTICS OF THE KEY COUNTRIES/TERRITORIES
    • 13.6.4. MARKET STATISTICS

14. GLOBAL DIABETIC CARE MARKET: KEY PLAYERS

  • 14.1. INTRODUCTION
  • 14.2. ELI LILLY AND COMPANY
    • 14.2.1. OVERVIEW
    • 14.2.2. FINANCIALS
    • 14.2.3. KEY DEVELOPMENTS
    • 14.2.4. SWOT ANALYSIS
  • 14.3. BAYER HEALTHCARE AG
    • 14.3.1. OVERVIEW
    • 14.3.2. FINANCIALS
    • 14.3.3. KEY DEVELOPMENTS
    • 14.3.4. SWOT ANALYSIS
  • 14.4. NOVO NORDISK
    • 14.4.1. OVERVIEW
    • 14.4.2. FINANCIALS
    • 14.4.3. KEY DEVELOPMENTS
    • 14.4.4. SWOT ANALYSIS
  • 14.5. SANOFI PHARMA
    • 14.5.1. OVERVIEW
    • 14.5.2. FINANCIALS
    • 14.5.3. KEY DEVELOPMENTS
    • 14.5.4. SWOT ANALYSIS
  • 14.6. MEDTRONIC INCORPORATION
    • 14.6.1. OVERVIEW & FINANCIALS
    • 14.6.2. KEY DEVELOPMENTS
    • 14.6.3. SWOT ANALYSIS
  • 14.7. JOHNSON & JOHNSON
    • 14.7.1. OVERVIEW & FINANCIALS
    • 14.7.2. KEY DEVELOPMENTS
    • 14.7.3. SWOT ANALYSIS
  • 14.8. PFIZER
    • 14.8.1. OVERVIEW & FINANCIALS
    • 14.8.2. KEY DEVELOPMENTS
    • 14.8.3. SWOT ANALYSIS
  • 14.9. ASTRAZENECA
    • 14.9.1. OVERVIEW & FINANCIALS
    • 14.9.3. SWOT ANALYSIS
  • 14.1. MERCK & CO., INC
    • 14.10.1. OVERVIEW & FINANCIALS
    • 14.10.3. SWOT ANALYSIS
  • 14.11. ROCHE DIAGNOSTICS
    • 14.11.1. OVERVIEW & FINANCIALS
    • 14.11.3. KEY DEVELOPMENTS
    • 14.11.4. SWOT ANALYSIS
  • 14.12. BRISTOL-MYERS SQUIBB COMPANY
    • 14.12.1. OVERVIEW & FINANCIALS
    • 14.12.2. SWOT ANALYSIS
  • 14.13. BOEHRINGER INGELHEIM GROUP
    • 14.13.1. OVERVIEW & FINANCIALS
    • 14.13.2. SWOT ANALYSIS
  • 14.14. ABBOTT LABORATORIES
    • 14.14.1. OVERVIEW & FINANCIALS
    • 14.14.2. SWOT ANALYSIS
  • 14.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 14.15.1. OVERVIEW & FINANCIALS
    • 14.15.2. SWOT ANALYSIS
  • 14.16. GLAXOSMITHKLINE PLC (GSK)
    • 14.16.1. OVERVIEW
    • 14.16.2. FINANCIALS
  • 14.17. NOVARTIS
    • 14.17.1. OVERVIEW & FINANCIALS
  • 14.18. AT&T, INC.
    • 14.18.1. OVERVIEW & FINANCIALS
  • 14.19. AGAMATRIX, INC.
    • 14.19.1. OVERVIEW & DEVELOPMENTS

15. LIST OF ACCRONYMS

LIST OF FIGURES

  • 1. REPORT COVERAGE
  • 2. RESEARCH METHODOLOGY
  • 3. YEAR CONSIDERATION FOR REPORT
  • 4. GLOBAL DIABETIC CARE MARKET($BILLION)
  • 5. GLOBAL DIABETIC CARE MARKET SHARE, BY DIABETES TYPE, 2014-2022($BILLION)
  • 6. GLOBAL DIABETIC CARE MARKET SIZE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 7. GLOBAL DIABETIC CARE MARKET SIZE, BY END-USE APPLICATION, 2014-2022($BILLION)
  • 8. GLOBAL DIABETIC CARE MARKET SIZE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 9. TYPES OF DIABETES
  • 10. DIABETES PREVALENCE WORLDWIDE PER REGION IN 2015 AND 2040(20-79 YEARS)
  • 11. RISK FACTORS FOR DIABETIC CARE
  • 12. APPROACH OF DIABETES MANAGEMENT
  • 13. ADVANCE TECHNOOGIES ENTERING INTO DIABETIC CARE
  • 14. MARKET DYNAMICS
  • 15. PORTER'S FIVE FORCES ANALYSIS
  • 16. BARGAINING POWER OF BUYERS
  • 17. BARGAINING POWER OF SUPPLIER
  • 18. THREAT FROM SUBSTITUTE
  • 19. THREAT OF NEW ENTRANT
  • 20. INTENSITY OF COMPETITIVE RIVALRY
  • 21. ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS
  • 22. CLASSIFICATION OF MEDICAL DEVICES
  • 23. VALUE CHAIN ANALYSIS
  • 24. TYPE OF DIABETES
  • 25. GLOBAL DIABETIC CARE MARKET VALUE, BY TYPE OF DIABETES($BILLION)
  • 26. GLOBAL DIABETIC CARE MARKET VALUE, BY TYPE 1 DIABETES($BILLION)
  • 27. GLOBAL DIABETIC CARE MARKET VALUE, BY TYPE 2 DIABETES($BILLION) T2D, BY GEOGRAPHY 2014
  • 28. GLOBAL DIABETIC CARE MARKET VALUE, BY GESTATIONAL DIABETES($BILLION)
  • 29. GLOBAL DIABETIC CARE MARKET VALUE, BY OTHER DIABETES($BILLION)
  • 30. DIABETIC CARE ECOSYSTEM CLASSIFICATION
  • 31. GLOBAL DIABETIC CARE MARKET BY ECOSYSTEM PLAYERS
  • 32. GLOBAL DIABETIC CARE MARKET VALUE, BY DRUG MANUFACTURERS, 2014-2022($BILLION)
  • 33. GLOBAL DIABETIC CARE DRUG MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 34. GLOBAL DIABETIC CARE DRUG MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 35. GLOBAL DIABETIC CARE DRUG MARKET
  • 36. GLOBAL DIABETIC CARE DRUG MARKET VALUE, BY DRUG TYPES, 2014-2022($BILLION)
  • 37. MEDICINES IN DEVELOPMENT FOR DIABETES
  • 38. DRUG DEVELOPMENT PROCESS
  • 39. INSULIN TYPES
  • 40. GLOBAL OADS DIABETIC CARE MARKET, 2014-2022($BILLION)
  • 41. GLOBAL NON-INSULIN INJECTABLE DRUGS MARKET, 2014-2022($BILLION)
  • 42. GLOBAL DIABETIC CARE MARKET BY DEVICE TYPES
  • 43. GLOBAL DIABETIC CARE DEVICE MARKET VALUE, BY DEVICE MANUFACTURER, 2014-2022($BILLION)
  • 44. GLOBAL DIABETIC CARE DEVICE MARKET VALUE, BY DEVICE TYPES, 2014-2022($BILLION)
  • 45. GLOBAL DIABETIC CARE DEVICE MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 46. GLOBAL DIABETIC CARE DEVICE MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 47. GLUCOSE MONITORING DEVICES
  • 48. SMBG DEVICE USES
  • 49. INSULIN DELIVERY DEVICES TYPES
  • 50. GLOBAL INSULIN DELIVERY DEVICE MARKET, 2014-2022,($BILLION)
  • 51. DIABETES MOBILE APPLICATIONS
  • 52. BENEFITS OF BIG DATA
  • 53. BIG DATA CHALLENGES
  • 54. GLOBAL DIABETIC CARE MARKET VALUE, BY APPLICATION DEVELOPERS, 2014-2022($BILLION)
  • 55. APPLICATION DEVELOPERS DIABETIC CARE MARKET VALUE, BY END-USE APPLICATION TYPES, 2014-2022($BILLION)
  • 56. APPLICATION DEVELOPERS DIABETIC CARE MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 57. BENEFITS OF MOBILE APPS
  • 58. TYPE OF DIABETES APPS
  • 59. GLOBAL DIABETIC CARE MARKET BY END-USE APPLICATIONS
  • 60. GLOBAL DIABETIC CARE MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 61. GLOBAL DIABETIC CARE MARKET VALUE, BY PATIENT MONITORING, 2014-2022($BILLION)
  • 62. GLOBAL DIABETIC CARE PATIENT MONITORING MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 63. GLOBAL DIABETIC CARE PATIENT MONITORING MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 64. DIAGNOSIS APPLICATION
  • 65. GLOBAL DIABETIC CARE DIAGNOSIS MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 66. GLOBAL DIABETIC CARE DIAGNOSIS MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 67. EDUCATION & AWARENESS SERVICES
  • 68. GLOBAL DIABETIC CARE EDUCATION & AWARENESS MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 69. GLOBAL DIABETIC CARE EDUCATION & AWARENESS MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 70. HEALTHCARE MANAGEMENT
  • 71. GLOBAL DIABETIC CARE HEALTHCARE & MANAGEMENT MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 72. GLOBAL DIABETIC CARE HEALTHCARE & MANAGEMENT MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 73. GLOBAL DIABETIC CARE WELLNESS & PREVENTION MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 74. GLOBAL DIABETIC CARE WELLNESS & PREVENTION MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 75. GLOBAL DIABETIC CARE TREATMENT MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 76. GLOBAL DIABETIC CARE TREATMENT MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 77. GLOBAL DIABETIC CARE OTHER END-USE APPLICATIONS MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 78. GLOBAL DIABETIC CARE OTHER END-USE APPLICATIONS MARKET VALUE, BY GEOGRAPHY, 2014-2022($BILLION)
  • 79. GLOBAL DIABETIC CARE MARKET, BY GEOGRAPHY
  • 80. FIGURE: THE AMERICAS DIABETIC CARE MARKET, BY SUB-REGIONS 2014($BILLION)
  • 81. THE AMERICAS DIABETIC CARE MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 82. THE AMERICAS DIABETIC CARE MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 83. THE U.S. DIABETIC CARE MARKET, 2014-2022($BILLION)
  • 84. EUROPE DIABETIC CARE MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 85. EUROPE DIABETIC CARE MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 86. APAC DIABETIC CARE MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 87. APAC DIABETIC CARE MARKET VALUE, BY END-USE APPLICATIONS, 2014-2022($BILLION)
  • 88. ROW DIABETIC CARE MARKET VALUE, BY SUB-REGION($BILLION)
  • 89. ROW DIABETIC CARE MARKET VALUE, BY ECOSYSTEM, 2014-2022($BILLION)
  • 90. ROW DIABETIC CARE MARKET VALUE, BY END-USE APPLICATIONS($BILLION)
  • 91. ELI LILLY AND COMPANY: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 92. ELI LILLY AND COMPANY: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 93. ELI LILLY AND COMPANY: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 94. ELI LILLY AND COMPANY: FINANCIALS BY HUMAN PHARMACEUTICAL SUB-SEGMENT,(2014)
  • 95. ELI LILLY AND COMPANY: SWOT ANALYSIS
  • 96. BAYER HEALTHCARE AG: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 97. BAYER HEALTHCARE AG: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 98. BAYER HEALTHCARE AG: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 99. BAYER HEALTHCARE AG: FINANCIALS BY HEALTHCARE SUB-SEGMENT,(2014)
  • 100. NOVO NORDISK: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 101. NOVO NORDISK: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 102. NOVO NORDISK: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 103. NOVO NORDISK: SWOT ANALYSIS
  • 104. SANOFI PHARMA: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 105. SANOFI PHARMA: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 107. SANOFI PHARMA: SWOT ANALYSIS
  • 108. MEDTRONIC INCORPORATION: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 109. MEDTRONIC INCORPORATION: SWOT ANALYSIS
  • 110. JOHNSON & JOHNSON: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 111. JOHNSON & JOHNSON: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 112. JOHNSON & JOHNSON: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 113. JOHNSON & JOHNSON: SWOT ANALYSIS
  • 114. PFIZER: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 115. PFIZER: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 116. PFIZER: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 117. PFIZER: SWOT ANALYSIS
  • 118. ASTRAZENECA: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 119. ASTRAZENECA: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 120. ASTRAZENECA: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 121. ASTRAZENECA: SWOT ANALYSIS
  • 122. MERCK & CO., INC.: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 123. MERCK & CO., INC.: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 124. MERCK & CO., INC.: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 125. MERCK & CO., INC.: SWOT ANALYSIS
  • 126. ROCHE DIAGNOSTICS: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 127. ROCHE DIAGNOSTICS: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 128. ROCHE DIAGNOSTICS: FINANCIALS BY GEOGRAPHY, 2012-2014,($BILLION)
  • 129. ROCHE DIAGNOSTICS: SWOT ANALYSIS
  • 130. BRISTOL-MYERS SQUIBB COMPANY: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 131. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)
  • 146. GSK: FINANCIALS BY GEOGRAPHY,(2014)
  • 147. GSK: FINANCIALS BY PHARMACEUTICAL SUB-SEGMENT,(2014)
  • 148. NOVARTIS: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 149. NOVARTIS: FINANCIALS BY BUSINESS SEGMENT,(2014)
  • 150. NOVARTIS: FINANCIALS BY REGION,(2014)
  • 151. AT&T, INC.: OVERALL FINANCIALS, 2012-2014,($BILLION)
  • 152. AT&T, INC.: FINANCIALS BY BUSINESS SEGMENTS, 2012-2014,($BILLION)

LIST OF TABLES

  • 1. GLOBAL DIABETIC CARE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022($BILLION)
  • 2. SOME DIABETIC DRUGS
  • 3. SOME OF THE KEY PRODUCTS IN THE DIABETIC CARE MOBILE APPS MARKET
  • 4. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
  • 5. BAYER HEALTHCARE AG: RECENT DEVELOPMENTS
  • 6. NOVO NORDISK: RECENT DEVELOPMENTS
  • 7. SANOFI PHARMA: RECENT DEVELOPMENTS
  • 8. MEDTRONIC INCORPORATION: RECENT DEVELOPMENTS
  • 10. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
  • 11. PFIZER: RECENT DEVELOPMENTS
  • 12. ROCHE DIAGNOSTICS: RECENT DEVELOPMENTS
Back to Top